Document Detail


Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
MedLine Citation:
PMID:  17600286     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite the use of combination therapy with pegylated interferon alpha2a (peg-IFN-alpha2a) + Ribavirin, a large proportion of patients with chronic hepatitis C (CHC) remain unresponsive to treatment. Thymosin alpha 1 (Talpha1) is an immunomodulator, which displays immunological and antiviral activities against hepatitis C virus (HCV) in preclinical clinical settings. The purpose of this study was to evaluate the efficacy and safety of a triple combination therapy with peg-IFN-alpha2a + Ribavirin + Talpha1 in CHC patients who were nonresponders to a previous course with peg-IFN-alpha2a + Ribavarin. The primary endpoint is the rate of sustained virological response (SVR). We designed a phase 3, randomized, double-blind, multicenter, prospective, placebo controlled study. Patients meeting selection criteria were randomized centrally (through IVR system) to receive either peg-IFN-alpha2a 180 mcg s.c. once weekly + Ribavirin 1000-1200 mg p.o. daily + Talpha1 1.6 mg s.c. twice weekly for 24 weeks. Patients who remained HCV-RNA positive after 24 weeks stopped treatment and were considered nonresponders. HCV-RNA negative patients continued treatment up to week 48. All patients were followed up for 24 additional weeks after the end of treatment for the evaluation of the SVR. From December 2004 to November 2006, 638 patients were screened in 52 European sites. Preliminary blinded safety analysis suggests that both regimens are well tolerated. Efficacy evaluation will be available after the opening of this blinded phase 3 trial, planned for May 2008.
Authors:
Roberto Camerini; Alessia Ciancio; Alfonso DE Rosa; Mario Rizzetto
Related Documents :
3298406 - A controlled trial of 6 months thrice weekly lymphoblastoid interferon versus no therap...
10607236 - Histological and virological long-term outcome in patients treated with interferon-alph...
12578736 - -dual nucleoside therapy for hiv infection: analysis of results and factors influencing...
2247806 - Subcutaneous interferon alpha in the treatment of refractory condylomata.
17070426 - Impact of baseline echocardiography on treatment outcome in primary care patients with ...
22057006 - Atraumatic osteonecrosis of the distal radius and ulna: case series and review.
Publication Detail:
Type:  Journal Article     Date:  2007-06-28
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1112     ISSN:  0077-8923     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-10-19     Completed Date:  2007-12-27     Revised Date:  2008-01-25    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  368-74     Citation Subset:  IM    
Affiliation:
Clinical Research Unit III, Sigma-Tau S.p.A., Pomezia, Italy. roberto.camerini@sigma-tau.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / therapeutic use
Clinical Trials as Topic
Drug Administration Schedule
Drug Therapy, Combination
Hepatitis C, Chronic / drug therapy*
Humans
Interferon Alfa-2a / therapeutic use*
Polyethylene Glycols / therapeutic use*
Ribavirin / therapeutic use
Thymosin / analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/peginterferon alfa-2a; 0/thymalfasin; 36791-04-5/Ribavirin; 61512-21-8/Thymosin; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification and quantification of thymosin beta4 in human saliva and tears.
Next Document:  Thymosin fraction-5 possesses antiproliferative properties in HL-60 human promyelocytic leukemia cel...